In addition, a murine TCR isolated from humanized mice20, and a bispecific T cell engaging TCR-mimetic antibody targeting KRASG12V peptides in the context of HLA-A*11:01 (HLA-A*11) and HLA-A*03:013, respectively, have demonstrated T cell activation and killing of cancer cells preclinically. This evidence concerns the gene HLA-A and cancer.